Mylan Launches Generic Version of Qualaquin® Capsules

            Mylan Launches Generic Version of Qualaquin® Capsules

PR Newswire

PITTSBURGH, Dec. 18, 2012

PITTSBURGH, Dec. 18, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals Inc. has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This
product is the generic version of Mutual Pharmaceutical Company, Inc.'s
Qualaquin^® Capsules, and is an antimalarial drug indicated only for treatment
of uncomplicated Plasmodium falciparum malaria.(1)

Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9
million for the 12 months ending Sept. 30, 2012, according to IMS Health.
Mylan has begun shipping this product.

Currently, Mylan has 178 ANDAs pending FDA approval representing $79.2 billion
in annual sales, according to IMS Health. Thirty-five of these pending ANDAs
are potential first-to-file opportunities, representing $21.2 billion in
annual brand sales, for the 12 months ending June 30, 2012, according to IMS
Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service a habit, do what's right, not what's easy and impact
the future through passionate global leadership. We offer a growing portfolio
of more than 1,100 generic pharmaceuticals and several brand medications. In
addition, we offer a wide range of antiretroviral therapies, upon which
approximately one-third of HIV/AIDS patients in developing countries depend.
We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

(1) Quinine Sulfate Capsules are not approved for the treatment or prevention
of nocturnal leg cramps and use for such treatment may result in serious and
life-threatening hematologic reactions, including thrombocytopenia and
hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP).
Chronic renal impairment associated with the development of TTP has been
reported.

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Media, Nina Devlin, +1-724-514-1968, or Investors, Kris King,
+1-724-514-1813